Posted by Michael Wonder on 20 Sep 2025
Merck receives positive EU CHMP opinion for Enflonsia (clesrovimab) for the prevention of respiratory syncytial virus in infants during their first RSV season
19 September 2025 - If approved by the European Commission, Enflonsia will be the first and only RSV preventive option in Europe for administration to infants using the same dose regardless of weight
Merck announced today that the CHMP of the EMA recommended the approval of Enflonsia (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants during their first RSV season.
